No profile data available.
Arrowhead Pharmaceuticals, Inc. (ARWR) is a healthcare company in the hepatic treatment pharmaceuticals industry, based in Pasadena, United States, with about 711 full-time employees.
It reported revenue of $829.45 million for fiscal year 2025, and net income of -$1.63 million. In Q3 2026 (the quarter ended June 30, 2026) revenue was $75.25 million. Its market capitalization was $8.84 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended September 30, 2025; market data as of October 9, 2026.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Arrowhead Pharmaceuticals reported $829.45 million in revenue for fiscal year 2025. In Q3 2026 revenue was $75.25 million.
$8.84 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (hepatic treatment pharmaceuticals) include Madrigal Pharmaceuticals, Inc. (MDGL), Mirum Pharmaceuticals, Inc. (MIRM), Inventiva S.a. (IVA), Wave Life Sciences Ltd. (WVE).